Iktos
Generative design (Makya) and retrosynthesis (Spaya) software joined to robotic synthesis and in-house biology testing, used for partners and its own drug programmes.
Money and evidence
Latest round, Series A, 2023-03-09: the record then held no research entry for the company. The first research entry is dated 2025-11-28; the highest level so far is 4 (Tested in the physical world).
Rounds and research, on one timeline
- 2026-07-13Research
Level 4 · Tested in the physical world
A PolQ inhibitor scaffold from Iktos's generative model reaches low-nanomolar potency in the test tube, and its most potent compound is inactive in cells
This is a generative design carried through synthesis and assays rather than a docking score, and the paper credits model and chemists together without separating their shares. The cell assay is where it stops: the 8.3 compound showed no potency against BRCA-deficient cells, which the authors put down to poor permeability, so the biochemical gain did not carry into cells. Every number comes from the two companies whose staff wrote the paper, and selectivity against related enzymes and any animal test are still to come.
- 2025-11-28Research
Level 4 · Tested in the physical world
Iktos's robot runs 135 reactions of 27 kinds in six batches by grouping them on temperature and time, and finds the product in 97
Generative models propose lists of unrelated molecules, and robots built for one-chemistry libraries stall on exactly that, so this works on the make step where AI design meets the bench. The bar for success is the product seen at 5% of the UV trace, not isolated yield, and purified yields ran 4 to 48%. Chemists still chose the targets, the conditions and the reruns: this is a scheduling method for a robot, not an autonomous lab.
- 2023-03-09Series ARound
€15.5M≈ $16.4M
For: AI capabilities, SaaS offering, launching Iktos Robotics
Models and platformCommercial roll-outAutomated lab
Co-lead · M Ventures ✓Co-lead · Debiopharm Innovation Fund ✓Omnes Capital ✓
On the deal: Nadiya Ishnazarova (Spoke for the investors, M Ventures); Tanja Dowe (CEO, Debiopharm Innovation Fund)
The investor's own page says · Debiopharm Innovation Fund: Series A 2023
The investor's own page says · Omnes Capital: Investment Date 2022
Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.
On the investors' own sites
Investors that name this company on their own site, in a portfolio or their own announcement. A ✓ in a round marks the same investor.
- Debiopharm Innovation FundSeries A 2023debiopharm.com ↗
- M Venturesm-ventures.com ↗
- Omnes CapitalInvestment Date 2022omnescapital.com ↗
Its investors also backed
Other companies on this page whose rounds name the same investor.
- Debiopharm Innovation FundWhiteLab Genomics
- M VenturesLabGenius
- Omnes CapitalWhiteLab Genomics